Allogene Therapeutics, Inc. (ALLO)

Market Cap	493.39M
Revenue (ttm)	95,000
Net Income (ttm)	-327.27M
Shares Out	169.09M
EPS (ttm)	-2.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,424,911
Open	2.870
Previous Close	2.855
Day's Range	2.750 - 2.930
52-Week Range	2.230 - 6.890
Beta	0.80
Analysts	Buy
Price Target	15.39 (+432.53%)
Earnings Date	May 10, 2024

About ALLO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 fo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 232
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLO

Financial Performance

In 2023, ALLO's revenue was $95,000, a decrease of -39.10% compared to the previous year's $156,000. Losses were -$327.27 million, -3.86% less than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is $15.39, which is an increase of 432.53% from the latest price.

Price Target

$15.39

(432.53% upside)

Analyst Consensus: Buy